[Ezetimibe (Ezetrol) in patients with diabetes].
Ezetimibe (Ezetrol) selectively inhibits the intestinal absorption of cholesterol and phytosterols. Its mechanism of action results in a synergistic cholesterol-lowering effect together with a statin that inhibits cholesterol synthesis by the liver, which leads to the development of a fixed ezetimibe-simvastatin combination (Inegy). Ezetimibe has been more particularly studied in patients with type 2 diabetes whose high cardiovascular risk is well known. The present article aims at describing recent advances and specificities concerning the use of ezetimibe in the diabetic population.
Université de Liège.
A J
AJ
Scheen
R P
RP
Radermecker
D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D000069438:Ezetimibe; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D000069438:Ezetimibe